Conflicts of Interest The authors declare no conflicts of interest. Supporting Information Filename Description rcm10141-sup-0001-Suppl-file.docxWord 2007 document , 297.6 KB Figure S1: LC-HRMS chromatograms of resigratinib and its metabolites following 60-min incubation with recombinant P450s. References 1, , , et al., “FGF/FGFR Signaling in Health and Disease,” Signal Transduction and Targeted Therapy 5, no. 1 (2020): 181, https://doi.org/10.1038/s41392-020-00222-7.
